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Abstract
Background: Resection for pancreatic neuroendocrine tumours (PNET) is suggested to be associated
with an increased risk of a post-operative pancreatic fistula (POPF). The aim of this study was to describe
morbidity after resections for PNET, focusing on POPF. Outcomes were compared with resections for
other lesions.
Methods: Patients undergoing an elective pancreatic resection during a 12-year period were retrospec-
tively analysed. Morbidity was defined according to the International Study Group of Pancreatic Surgery
(ISGPS) definitions.
Results: Eighty-eight out of 832 patients (10.6%) underwent a resection for PNET. Atypical pancreatic
resections (enucleation and central pancreatectomy) and distal pancreatectomies were more frequently
performed for PNET. The POPF rate was 22.7% in patients operated for PNET compared with 17.2% in
other patients (P = 0.200). In univariate analysis, body mass index (BMI), pancreatic duct diameter,
somatostatin analogue administration, type of resection and type of pathology were associated with a
POPF. In multivariate analysis, BMI, a pancreatic duct diameter <3 mm and central pancreatectomy
remained independent risk factors [odds ratio (OR) 1.93, 95% confidence interval (CI) 1.22–3.07 and OR
3.04, 95% CI 1.05–8.82, respectively].
Conclusions: High rates of POPF were found in patients operated for PNET. However, this was mainly
owing to the fact that atypical resections, known to be associated with a higher fistula rate, were
performed more frequently in these patients.
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Introduction
Pancreatic neuroendocrine tumours (PNET) are malignancies of
the pancreas with a reported incidence of <1 per 100 000
persons per year.1 Although PNET only comprise approximately
3% of all pancreatic neoplasms, autopsy studies have indicated
that PNET are much more common; incidence rates up to
10% in patients undergoing extensive pathological post-mortem
examination are described.2,3 Furthermore, the incidence is
increasing, partly explained by growing numbers of inciden-
tally detected PNET owing to the more frequent use of
imaging.1,4–6
PNET can be divided into functional and non-functional
tumours (NF-PNET). Functional PNET secrete hormones, such
as insulin, gastrin and glucagon, all causing a specific hormonal
syndrome. Non-functional tumours, estimated to make up 90% of
all PNET, are not associated with a specific hormonal syndrome
either because no peptide is secreted or the secreted substance
does not cause any symptoms.1
In contrast to pancreatic adenocarcinoma, most PNET have an
indolent tumour biology. Nevertheless, surgery is the treatment of
choice for resectable disease and selected cases with resectable
metastases.7–11 However, controversy remains regarding several
surgical aspects of PNET, such as the role of atypical resections
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(enucleations and central pancreatectomies), resection of the
PNET primary in case of metastases and the surgical management
of possibly benign, small (<2 cm) NF-PNET.11–16
An important determinant in the surgical approach of patients
with PNET is post-operative morbidity. Although mortality after
a pancreatic resection has decreased below 5% in high-volume
centres, morbidity remains high (40–70%).17,18 A post-operative
pancreatic fistula (POPF) is one of the most frequent, potentially
life-threatening complications and can originate from the pancre-
atic remnant after a distal pancreatectomy (DP) or enucleation, as
well as from an anastomosis such as the pancreaticojejunostomy
or pancreatico-gastrostomy.19 Several histomorphological features
of the pancreas have been associated with POPF. Soft consistency
of the pancreatic parenchyma is regarded as a risk factor for fistula
development, as well as small pancreatic duct size and fatty
pancreas.20–24 Underlying pathology is also correlated with the
incidence of POPF as adenocarcinoma and chronic pancreatitis
are typically associated with firm, fibrotic and thereby easily
sutured glands, whereas other peri-ampullary cancers and benign
processes are associated with a soft gland.20,21 PNET rarely cause
duct dilatation and fibrosis, and could therefore be associated with
increased rates of POPF.8,20,21,25
In this study, we describe a cohort of patients undergoing a
resection for PNET at a referral centre for pancreatic lesions.
Post-operative morbidity is compared between patients operated
for PNET and patients undergoing a pancreatic resection for other
diseases, with special interest in the incidence of a pancreatic
fistula.
Patients and methods
A consecutive series of patients undergoing an elective pancreatic
resection during a 12-year period at a tertiary referral centre was
analysed. Local pancreatic head resections combined with a
pancreaticojejunostomy for chronic pancreatitis and total
pancreatectomies were excluded. Furthermore, pancreatic tail
resections, as part of extended oncological multivisceral resec-
tions (e.g. for stomach or colonic cancer), as well as pancreatic
resections for abdominal trauma were also excluded.
Data concerning patients treated with a pancreatoduodenec-
tomy (PD) were gathered from a prospectively registered data-
base. Patients undergoing other types of pancreatic resection were
identified using electronic administrative databases and data were
retrospectively collected. The clinical records of all patients
were analysed with regard to fulfilling the criteria of this study.
Clinicopathological data, demographics and post-operative out-
comes were assessed. Main pancreatic duct diameter and size of
neuroendocrine tumours were based upon measurements on
pre-operative computed tomography. In case of multiple
neuroendocrine lesions, the size of the largest lesion was noted.
Because the present study involved a retrospective analysis of
anonymized data, the Dutch Ethical Review Board regulations do
not require informed consent.
Surgical procedures
The standard surgical procedure for suspected malignancy
(including grade 3 neuroendocrine neoplasms) of the pancreatic
head was a pylorus-preserving PD with removal of the lymph
nodes on the right side of the portal vein, as described earlier.26,27
In case of tumour ingrowth in the pylorus or duodenum, a
classic Whipple’s resection was performed. Reconstruction was
performed by end-to-side pancreaticojejunostomy, end-to-side
hepaticojejunostomy and a duodeno – or gastrojejunostomy on
the same jejunal limb, without Roux-en-Y reconstruction.
Lesions of the pancreas body and/or tail were treated with a DP
with or without spleen preservation. The decision to include a
splenectomy was made intra-operatively, taking into account the
patient’s underlying disease as well as the curative intention.
The pancreatic remnant was closed either by stapler or hand-
sewn, depending on the patients participation in a trial, or the
surgeons preference.28 A central pancreatectomy (CP), also
known as a middle or median pancreatectomy, was performed
only for small benign or low-grade malignant neoplasms and
metastases from extrapancreatic malignancies (renal cell carci-
noma), located in the pancreatic body. The transected pancreatic
head was stapled or sutured and an end-to-side Roux-en-Y
pancreaticojejunostomy was anastomosed to the pancreatic tail.
Enucleation was considered for superficial insulinomas, non-
functioning tumours smaller than 2 cm and small cystic neo-
plasm, taking into account that the main pancreatic duct could
safely be preserved. When in doubt, an intra-operative ultra-
sonography was performed. On occasion, an absorbable fibrin
sealant patch was used if there was a high anticipated risk of a
post-operative pancreatic fistula.
A prophylactic, intraperitoneal drain was placed routinely after
all pancreatic resections (except after enucleations) and was gen-
erally removed after 4–5 days, earlier if output had ceased and the
condition of the patient justified its removal. Somatostatin ana-
logues (100 μg subcutaneously 3 times/day) or long-acting soma-
tostatin analogues (120 mg intragluteal 1/28 days) were
administered prophylactically to patients at risk of developing a
pancreatic fistula (non-dilated pancreatic duct and/or soft pan-
creatic tissue), and as short-time treatment for an established
POPF.
Underlying disease
The diagnosis of the underlying disease was based upon histopa-
thology reports. Neuroendocrine tumours were considered non-
functional if no clinical symptoms of hormonal excess were
present. Insulinomas were biochemically diagnosed using a 72-h
supervised fasting test. The diagnosis of gastrinoma was estab-
lished by measuring elevated fasting gastrin levels. VIPoma was
confirmed by raised serum vasoactive intestinal peptide levels.
Patients were considered as having carcinoid syndrome if tumour
symptoms were accompanied with evidence of serotonin,
tachykinin or prostaglandin secretion.
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Outcome measures
Primary evaluated outcome was morbidity after surgery. A POPF,
delayed gastric emptying (DGE) and a post-operative haemor-
rhage (PPH) were defined according to the International Study
Group of Pancreatic Surgery (ISGPS) definitions.29–31 For these
specific complications, grades B and C were considered clinically
relevant. An abdominal abscess was defined as a fluid collection
with positive bacterial culture. Other peri-operative outcome
parameters were: the need for reoperation, duration of hospital
stay, readmission within 30 days and peri-operative mortality
defined as death in hospital.
Statistical analysis
For all statistical analyses PASW Statistics 18.0.2 was used (SPSS
Inc, Chicago, IL, USA).
Results are presented as mean ± SD or median with
interquartile range (IQR) depending on the distribution of the
data. Comparison between patients with PNET and patienta with
other indications for a pancreatic resection was performed using
the χ2 test or Fisher’s exact test for categorical data, and the inde-
pendent t-test or the Mann–Whitney U-test for continuous data,
depending on the distribution. Univariate logistic regression
analysis was performed to identify risk factors for the develop-
ment of a pancreatic fistula. Factors with a P-value of ≤0.20 and
factors with clinical plausibility for impacting outcome were con-
sidered for inclusion in multivariate regression analysis. In order
to include all patients in the multivariate analysis, missing values
of body mass index (BMI) and pancreatic duct size were imputed
using multiple imputation with a creation of five datasets. Multi-
variate logistic regression analysis was done in the five imputed
datasets and the outcomes were pooled. Results are shown as odds
ratio’s (OR) and 95% confidence intervals (CI). In all analyses,
P < 0.05 was considered to indicate statistical significance.
Results
Patient characteristics
During the study period, 832 consecutive patients underwent an
elective pancreatic resection and fulfilled the inclusion criteria. Of
these, 88 patients (10.6%) underwent a surgical resection for
PNET. The remaining 744 patients underwent an elective pancre-
atic resection for other diseases (Table 1).
Of the 88 patients undergoing a resection for PNET, 64 patients
had a PNET defined as non-functional (72.7% of PNET). Twenty-
four patients had functioning neuroendocrine tumours (27.3%):
Table 1 Patient and operative characteristics of 88 patients with PNET and 744 patients with other diseases undergoing a pancreatic resection
PNET (n = 88) Other (n = 744) Total (n = 832) P-value
Age – Mean (SD) 55 (13.8) 62 (12.4) 61 (12.7) 0.001
Male gender – No (%) 39 (44.3) 410 (55.1) 449 (54.0) 0.055
ASA classification – No (%)
I 20 (22.7) 152 (20.4) 172 (20.7) 0.960
II 59 (67.0) 466 (62.6) 525 (63.1) 0.211
III/IV 9 (10.2) 126 (16.9) 135 (16.2) 0.088
Body Mass Index (kg/m2) – Mean (SD) 25.8 (4.4)a 24.6 (4.1)a 24.8 (4.1) 0.047
Comorbidity – No (%)
Cardiac 11 (12.5) 152 (20.4) 163 (19.6) 0.142
Diabetes mellitus 11 (12.5) 132 (17.7) 143 (17.2) 0.094
Hypertension 19 (21.6) 192 (25.8) 211 (25.4) 0.273
Pulmonary 4 (4.5) 73 (9.8) 77 (9.3) 0.082
Pancreatic duct diameter < 3 mm – No (%) 68 (77.3) 334 (47.7)b 402 (48.3) <0.001
Somatostatin analogue administration – No (%) 51 (58.0) 369 (49.6) 420 (50.5) 0.138
Surgical procedure – No (%)
Central pancreatectomy 9 (10.2) 11 (1.5) 20 (2.4) <0.001
Distal pancreatectomy 26 (29.5) 113 (15.2) 139 (16.7) <0.001
Spleen preserving (% of DP) 15 (57.7) 45 (39.8) 60 (43.2) 0.097
Enucleation 24 (27.3) 4 (0.5) 28 (3.4) <0.001
Pancreatoduodenectomy 29 (33.0) 616 (82.8) 645 (77.5) <0.001
Pylorus-preserving (% of PD) 24 (82.8) 546 (88.6) 570 (88.4) 0.335
P-values highlighted in bold and italicized are considered to indicate statistical significance.
aFor 64 (72.7%) and 496 patients (66.7%) data for calculation of BMI were available.
bFor 269 patients (80.5%) data on pancreatic duct size were available.
PNET, pancreatic neuroendocrine tumour; SD, standard deviation; ASA, American Society of Anesthesiologists; PD, pancreatoduodenectomy; DP,
distal pancreatectomy.
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insulinomas (18/88; 20.5%), gastrinomas (3/88; 3.4%), carcinoids
(2/88; 2.3%) and VIPoma (1/88; 1.1%). Of the PNET, 52/88
(59.1%) were classified as grade 1, 25/88 (28.4) as grade 2 and 5/88
tumours (5.7%) were classified grade 3.26 The remaining six
tumours (6.8%) could not be classified. The median PNET size
was 21 mm (range 7–150).
Seven hundred forty-four patients (89.4%) underwent a
pancreatic resection for other diseases. Two hundred forty-
four patients (29.3%) had pancreatic adenocarcinoma as the
underlying disease and eighty-six patients (10.3%) had chronic
pancreatitis. One hundred and forty-one patients (17.3%) had
miscellaneous pancreatic diseases: serous and mucinous
cystadenomas (35 and 22), intraductal papillary mucinous neo-
plasms (48), metastases from extrapancreatic malignancies (15),
solid pseudopapillary neoplasms (6) and other pancreatic indica-
tions (15). The remaining 273 (32.8%) patients were operated for
non-pancreatic diseases: 135 (16.2%) ampullary carcinoma, 93
(11.2%) distal cholangiocarcinoma and 45 (5.4%) miscellaneous
non-pancreatic indications.
Patients undergoing a resection of PNET were significantly
younger and had a higher BMI compared with the other patients.
Furthermore, a small pancreatic duct size (<3 mm) was more
frequently found in patients with PNET.
Surgical procedures
Surgical procedures performed were 645 pancreatoduodenec-
tomies (77.5%), 139 distal pancreatectomies (16.7%), 20 central
pancreatectomies (2.4%) and 28 enucleations (3.4%). Regarding
distal pancreatectomies, the pancreas was transected using a sta-
pling device in 66 patients (47.5%), whereas the pancreatic
remnant was hand-sewn in 61 patients (43.9%). Five patients
(3.6%), all with chronic pancreatitis, had a pancreaticojejunos-
tomy anastomosed to the pancreatic head. In 7 patients (5.0%),
the technique of closure of the pancreatic remnant was unknown.
After a central pancreatectomy, the head was closed using staples
in 15 patients (75.0%) and hand-sewn in five (25.0%), the pan-
creatic tail was reconstructed with a pancreaticojejunostomy in all
patients. Three distal pancreatectomies were performed laparos-
copically (2.2%). In seven patients (4 distal pancreatectomies and
3 enucleations), an absorbable fibrin sealant patch was applied
after a pancreatic resection.
Enucleations, central pancreatectomies and distal pancrea-
tectomies were more often performed for neuroendocrine
tumours, whereas a pancreatoduodenectomy was less frequently
performed.
Post-operative outcome
The overall morbidity and mortality rate was 54.6% and 2.2%,
respectively (Table 2). Surgery-related complications occurred in
391 patients (47.0%). The median length of hospital stay was 11
days. A clinically relevant POPF was the most frequent surgical
complication after a resection for PNET (22.7%). In the group
undergoing a pancreatic resection for other indications, and the
Table 2 Post-operative complications and other outcomes in patients undergoing a pancreatic resection for PNET (n = 88) and other
diseases (n = 744)
PNET (n = 88) Other (n = 744) Total (n = 832) P-value
Any complication – No (%) 41 (46.6) 413 (55.5) 454 (54.6) 0.112
Surgical complications – No (%) 38 (43.2) 353 (47.4) 391 (47.0) 0.448
Pancreatic fistula grade B/Ca 20 (22.7) 128 (17.2) 148 (17.8) 0.200
Delayed gastric emptying grade B/Ca 11 (12.5) 209 (28.1) 220 (26.4) 0.002
Post-pancreatectomy haemorrhage grade B/C a 6 (6.8) 37 (5.0) 24 (4.3) 0.460
Wound infection 3 (3.4) 74 (9.9) 77 (9.3) 0.050
Other 10 (11.4) 72 (9.7) 82 (9.9) 0.616
Non-surgical complications – No (%) 12 (13.6) 172 (23.1) 184 (22.1) 0.043
Cardiac 3 (3.4) 46 (6.2) 49 (5.9) 0.469
Pneumonia 2 (2.3) 39 (5.2) 41 (4.9) 0.302
Other pulmonary 5 (5.7) 60 (8.1) 65 (7.8) 0.431
Urinary tract infection 4 (4.5) 55 (7.4) 59 (7.1) 0.507
Other 3 (3.4) 58 (7.8) 61 (7.3) 0.191
In-hospital mortality – No (%) 2 (2.3) 16 (2.2) 18 (2.2) 1.000
Reoperation – No (%) 6 (6.8) 59 (7.9) 65 (7.8) 0.713
Length of hospital stay in days – Median (IQR) 11 (10) 11 (9) 11 (9) 0.255
Hospital readmission within 30 days – No (%) 10 (11.4) 76 (10.2) 86 (10.3) 0.738
P-values highlighted in bold and italicized are considered to indicate statistical significance.
aAccording to the International Study Group of Pancreatic Surgery definition.
PNET, pancreatic neuroendocrine tumour; IQR, interquartile range; PJ, pancreaticojejunostomy.
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overall group, clinically relevant DGE had the highest incidence
(28.1% and 26.4%, respectively).
POPF
The overall clinically relevant pancreatic fistula rate was 17.8%
and did not change significantly during the study period. The
POPF rate subdivided according to type of underlying pathology
and type of pancreatic resection is shown in Table 3, The highest
rate of POPF was seen in patients operated for ampullary carci-
noma (24.4%), whereas patients operated for pancreatic adeno-
carcinoma had the lowest fistula rate (9.0%). Of the 88 patients
with a neuroendocrine tumour, 20 (22.7%) developed a grade B
or C POPF. Regarding type of resection, enucleation and a central
pancreatectomy were significantly associated with high rates
of POPF (35.7% and 40.0%, respectively) compared with a
pancreatoduodenectomy (17.7%) and distal pancreatectomy
(11.5%) (P ≤ 0.001).
In univariate analysis, BMI, pancreatic duct diameter, somato-
statin analogue administration, type of resection and type of
underlying pathology were associated with the risk of developing
a pancreatic fistula (Table 4). In multivariate analysis, BMI, pan-
creatic duct diameter <3 mm and a central pancreatectomy
remained independent risk factors for the development of a POPF
(OR 1.93, 95% CI 1.22–3.07 and OR 3.04, 95% CI 1.05–8.82,
respectively). PNET as underlying pathology was not associated
with post-operative fistula development.
Subanalysis of patients undergoing a
pancreatoduodenectomy
When only patients who underwent a pancreatoduodenectomy
(n = 645) were analysed, BMI, pancreatic duct diameter and type
of underlying pathology were associated with fistula development
in univariate analysis. In multivariate analysis, only BMI and pan-
creatic duct diameter remained independently associated with a
POPF (OR 1.11, 95% CI 1.04–1.18 and OR 2.09, 95% CI 1.28–
3.41, respectively).
Discussion
In this study, a consecutive series of 88 patients with PNET
undergoing a resection during a 12-year period at a tertiary refer-
ral centre was analysed. Mortality and morbidity was compared
with 744 patients undergoing pancreatic resections for other indi-
cations during the same period. The overall morbidity and mor-
tality was 54.6% and 2.2%, respectively. Patients operated for
PNET did not show a significantly higher pancreatic fistula rate
compared with patients operated for other diseases (22.7% versus
17.2%, P = 0.200). The type of underlying pathology was not in
independent risk factor for fistula development, except for a lower
fistula rate after a resection for pancreatic adenocarcinoma. A
central pancreatectomy, known to be associated with fistula
development and more frequently performed for neuroendocrine
tumours, was independently associated with a POPF, along with a
pancreatic duct diameter <3 mm and BMI.
The overall incidence of clinically relevant POPF (ISGPS grade
B/C) was 17.8%. The highest incidence of fistula development was
seen in patients operated for miscellaneous non-pancreatic dis-
eases (13/45, 28.9%), followed by ampullary carcinoma (33/135,
24.4). The lowest fistula rate was seen in patients undergoing
pancreatic resections for pancreatic adenocarcinoma (9.0%) and
chronic pancreatitis (15.1%). This is in line with previous reports
describing lower fistula rates after resections for pancreatic adeno-
carcinoma and chronic pancreatitis, in which the pancreatic
parenchyma is fibrotic and firm, and the pancreatic duct is fre-
quently dilated.32 Pancreatic lesions that usually do not cause
fibrotic reactions, such as PNET are generally not associated with
pancreatic duct obstruction. High fistula rates after resections for
PNET have been described accordingly.25,33
The type of pancreatic resection was strongly associated with
post-operative fistula development. Patients undergoing a central
pancreatectomy and enucleation had POPF rates of 40.0% and
35.7%, respectively. The high rate of pancreatic fistula after a
central pancreatectomy, in which there are two transected pancre-
atic surfaces, has been widely acknowledged and many series
report fistula rates greater than 30%.34–37 High rates of pancreatic
fistula after enucleation have also been reported.38 However, in
line with our data, enucleation is not always found to be an inde-
pendent predictor of fistula formation.33,39
In our study, multivariate analysis identified BMI, a pancreatic
duct diameter <3 mm and a central pancreatectomy as
Table 3 Post-operative pancreatic fistula rate subdivided according





Type of underlying pathology
Ampullary carcinoma 33/135 (24.4)
Chronic pancreatitis 13/86 (15.1)
Distal cholangiocarcinoma 22/93 (23.7)
Miscellaneous non-pancreatic disease 13/45 (28.9)
Miscellaneous pancreatic disease 25/141 (17.7)
Pancreatic adenocarcinoma 22/244 (9.0)†
PNET 20/88 (22.7)
Type of resection
Central pancreatectomy 8/20 (40.0)‡




†P ≤ 0.05 versus all other pathologies except chronic pancreatitis.
‡P ≤ 0.05 versus PD/PPPD and versus distal pancreatectomy.
PNET, pancreatic neuroendocrine tumour; PD, pancreatoduodenectomy;
PPPD, pylorus-perserving pancreatoduodenectomy.
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independent risk factors for the development of clinically relevant
POPF. The type of underlying disease was not independently asso-
ciated with POPF; we could not identify a neuroendocrine
tumour as an independent risk factor for fistula development, as
described earlier.25 The use of somatostatin analogues was not
independently associated with POPF either. Although clear evi-
dence is lacking, usage of somatostatin analogues in a risk-
dependant manner might be beneficial.40 The association of small
pancreatic duct size and high BMI with POPF development is in
line with previous reports.32,41,42
PNET are a diverse group of malignancies which compromise
only a small portion of all pancreatic neoplasms. Presentation and
prognosis differs considerably between types of PNET. However
for all types of PNET resection provides the only chance of a cure
and is the treatment of choice. Controversy remains regarding
several surgical aspects: for small (<2 cm) non-functional
neuroendocrine tumours, a non-operative approach can be advo-
cated and current guidelines recommend considering short- and
long-term sequelae of pancreatic resections in choosing the
appropriate treatment.11 As improved imaging techniques con-
tribute to growing incidence rates of small NF-PNET, this
dilemma is of increasing relevance. Correct patient selection is
paramount in order to optimize treatment results, especially
because pancreatic resections are still associated with high post-
operative morbidity. Another important aspect of pancreatic
surgery is the possibility to perform parenchyma-preserving
resections. These procedures can successfully lower the risk of
developing pancreatic endocrine and exocrine insufficiency.43–45
Table 4 Univariate and multivariate logistic regression analysis of patient- and surgery-related risk factors for a post-operative pancreatic
fistula (ISGPS grade B/C)
Univariate Multivariate
P-value Odds ratio 95% CI interval P-value
Age >59 years 0.889 – – –
Male gender 0.351 – – –
Body Mass Index (kg/m2)a <0.001 1.12 1.06–1.19 <0.001
ASA classification 0.725 – – –
I ref – – –
II 0.760 – – –
III/IV 0.660 – – –
Comorbidity
Cardiac 0.493 – – –
Diabetes mellitus 0.812 – – –
Hypertension 0.470 – – –
Pulmonary 0.303 – – –
Pancreatic duct diameter <3 mmb <0.001 1.93 1.22–3.07 0.005
Somatostatin analogue administration 0.026 0.93 0.62–1.39 0.723
Type of resection 0.002 – – –
PD/PPPD ref ref ref ref
Central pancreatectomy 0.015 3.04 1.05–8.82 0.041
Distal pancreatectomy 0.079 0.64 0.32–1.26 0.197
Enucleation 0.020 2.21 0.77–6.29 0.140
Type of underlying pathology 0.001 – – –
PNET ref ref ref ref
Ampullary carcinoma 0.768 2.17 0.91–5.13 0.079
Chronic pancreatitis 0.203 1.41 0.55–3.63 0.474
Distal cholangiocarcinoma 0.882 1.67 0.68–4.07 0.261
Miscellaneous pancreatic disease 0.356 1.16 0.53–2.43 0.710
Miscellaneous non-pancreatic disease 0.437 2.24 0.81–6.18 0.119
Pancreatic adenocarcinoma 0.001 0.75 0.32–1.80 0.525
aFor 560 patients (67.3%) data for calculation of BMI were available.
bFor 767 patients (92.2%) data regarding pancreatic duct diameter were available.
ASA, American Society of Anesthesiologists; PD, pancreatoduodenectomy; PPPD, pylorus-perserving pancreatoduodenectomy; PNET, pancreatic
neuroendocrine tumour.
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An increased risk of developing a pancreatic fistula after
parenchyma-preserving resections was shown, but these finding
can merely aid the decision-making process in choosing the
appropriate treatment.
This study has several limitations. Because of its retrospective
design regarding patients undergoing atypical resections and the
varying surgical details, we could not study the effect of various
resection and closure techniques which have been described in an
attempt to reduce the fistula rate. However, a large randomized
trial comparing stapler versus hand-sewn closure did not find any
effect and large comparative trials have yet to be published regard-
ing other closure techniques.28,46–49 Data regarding pancreatic
hardness were also lacking. Although experts agree that a ‘soft’
pancreas is a risk factor for fistula formation, there is no clear
definition. Palpatory assessment by experienced surgeons is sug-
gested to correlate well with quantitative measurements of pan-
creatic hardness by durometre, although this has to be confirmed
in large studies.50 Furthermore, we did not assess long-term pan-
creatic insufficiency, nor have we investigated survival. In spite of
these shortcomings, this study reports a large consecutive cohort
of pancreatic resections for PNET and other lesions from a single
institution, applying generally accepted ISGPS definitions of out-
comes after pancreatic surgery.
In conclusion, this study describes a consecutive series of
patients undergoing a resection for PNET at a single centre and
compares outcomes with patients undergoing a resection for
other diseases. Although a high pancreatic fistula rate was seen in
patients operated for PNET, this was due to the fact that atypical
resections such as central pancreatectomy and enucleation, which
are known to be associated with fistula development, were per-
formed more frequently in these patients. A neuroendocrine
tumour as underlying pathology was not independently associ-
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